Cypress Asset Management Inc. TX Has $4.52 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Cypress Asset Management Inc. TX increased its stake in Zoetis Inc. (NYSE:ZTS) by 4.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,195 shares of the company’s stock after buying an additional 1,228 shares during the quarter. Zoetis makes up 1.2% of Cypress Asset Management Inc. TX’s holdings, making the stock its 28th biggest position. Cypress Asset Management Inc. TX’s holdings in Zoetis were worth $4,522,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Hohimer Wealth Management LLC increased its position in Zoetis by 1.2% during the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after buying an additional 52 shares during the period. Forum Financial Management LP increased its position in shares of Zoetis by 0.8% in the fourth quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after purchasing an additional 56 shares during the period. Angeles Wealth Management LLC increased its position in shares of Zoetis by 3.5% in the fourth quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after purchasing an additional 56 shares during the period. Prossimo Advisors LLC increased its position in shares of Zoetis by 1.7% in the fourth quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after purchasing an additional 57 shares during the period. Finally, River Street Advisors LLC increased its position in shares of Zoetis by 3.4% in the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after purchasing an additional 58 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 1.0 %

Shares of ZTS stock traded down $1.83 during mid-day trading on Friday, reaching $180.59. 2,699,619 shares of the stock traded hands, compared to its average volume of 1,898,130. The stock’s fifty day simple moving average is $175.44 and its two-hundred day simple moving average is $175.72. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a market cap of $82.40 billion, a price-to-earnings ratio of 34.80, a price-to-earnings-growth ratio of 2.83 and a beta of 0.86. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period last year, the firm posted $1.31 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, research analysts anticipate that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s payout ratio is 33.14%.

Analysts Set New Price Targets

A number of research analysts recently commented on ZTS shares. HSBC decreased their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. BTIG Research began coverage on Zoetis in a research report on Thursday, July 25th. They issued a “buy” rating and a $220.00 price target on the stock. The Goldman Sachs Group reduced their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Stifel Nicolaus reduced their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Finally, Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average target price of $212.67.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.